• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

    2/14/24 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    VolitionRX Limited

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    928661107

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 928661107

     

    (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only):

     

    Lagoda Investment Management, L.P.

    46-4740139

       
    (2) Check the Appropriate Box if a Member of a Group (a) ☐  
      (b) ☐  
         
    (3) SEC Use Only    
    (4) Citizenship or Place of Organization    
      Delaware    

    Number of Shares Beneficially Owned By Each Reporting Person With    
      (5) Sole Voting Power: 3,728,600*  
      (6) Shared Voting Power: 0*  
      (7) Sole Dispositive Power: 3,728,600*  
      (8) Shared Dispositive Power: 0*  
           

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 3,728,600*

     

    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
      ☐
    (11) Percent of Class Represented by Amount in Row (9): 4.7%*
    (12) Type of Reporting Person (See Instructions): IA

     

    *See Item 4 for additional information.

     

     

     

     

    Item 1(a). Name Of Issuer:

     

    VolitionRX Limited (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    13215 Bee Cave Parkway

    Suite 125, Galleria Oaks B

    Austin, Texas 78738

     

    Item 2(a). Name of Person Filing:

     

    This report on Schedule 13G (this “Schedule 13G”) is being filed by Lagoda Investment Management, L.P. (the “Reporting Person”).

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The address for the Reporting Person is 3 Columbus Circle, New York, NY 10019.

     

    Item 2(c). Citizenship:

     

    The Reporting Person is organized under the laws of the State of Delaware.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, $0.001 par value per share (the “Common Stock”)

     

    Item 2(e). CUSIP No.:

     

    928661107

     

    Item 3. If This Statement Is Filed Pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the Person Filing is a:

     

    (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4. Ownership:

     

    As reported in the cover pages to this report, the ownership information with respect to the Reporting Person is as follows:

     

      (a) Amount Beneficially Owned: 3,728,600*
      (b) Percent of Class: 4.7%*
      (c) Number of Shares as to which such person has:  

     

      (i) Sole power to vote or to direct the vote: 3,728,600*
      (ii) Shared power to vote or to direct the vote: 0*
      (iii) Sole power to dispose or to direct the disposition of: 3,728,600*
      (iv) Shared power to dispose or to direct the disposition of: 0*

     

     

     

    * The Reporting Person serves as the investment manager to certain managed accounts (the “Accounts”) and possesses the sole power to vote and the sole power to direct the disposition of all securities of the Issuer held by the Accounts. The general partner of the Reporting Person is Lagoda Investment Management, LLC, a Delaware limited liability company (the “General Partner”). Fatima Dickey, as the sole member of the General Partner, possesses the voting and dispositive power with respect to all securities beneficially owned by the Reporting Person.

     

    As of December 31, 2023, the Accounts held 3,728,600 shares of Common Stock. Based on information disclosed in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, filed with the Securities and Exchange Commission on November 14, 2023, there were 78,685,873 shares outstanding as of November 7, 2023. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person beneficially owns 3,728,600 shares of Common Stock held in the aggregate by the Accounts.

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10. Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024  
       
    LAGODA INVESTMENT MANAGEMENT, L.P.  
         
    By: /s/ Jason A. Ozone  
    Name: Jason A. Ozone  
    Title: Chief Financial Officer & Chief Compliance Officer  

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $VNRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Volition Issues Business Review 2024

      HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

      1/8/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Timothy I. Still as Chairman

      HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

      11/6/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Dr. Ethel Rubin as an Independent Director

      HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

      9/30/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

      HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in

      6/4/25 9:00:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

      Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer. Frederic Wuilque, Vice President, Global Products, said: "This is an essential step in the development of Nu.Q® products for cats, our third species. This

      5/19/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    SEC Filings

    See more
    • SEC Form D filed by VolitionRX Limited

      D - VOLITIONRX LTD (0000093314) (Filer)

      5/30/25 4:13:34 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by VolitionRX Limited

      10-Q - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:27:40 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:26:48 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Innes Guy Archibald bought $10,772 worth of shares (20,000 units at $0.54), increasing direct ownership by 2% to 888,689 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/4/25 7:55:21 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO - Singapore Volition Kway Jasmine was granted 8,327 shares, increasing direct ownership by 5% to 191,107 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/3/25 4:07:04 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Nguyen Kim was granted 11,983 shares, increasing direct ownership by 14% to 98,392 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/3/25 4:06:49 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 4:05:14 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 3:40:04 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

      SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

      2/14/24 4:05:45 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on VolitionRx with a new price target

      H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

      4/8/25 8:02:28 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx downgraded by The Benchmark Company

      The Benchmark Company downgraded VolitionRx from Buy to Hold

      2/1/23 7:40:33 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

      Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

      2/17/22 9:10:02 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Innes Guy Archibald bought $10,772 worth of shares (20,000 units at $0.54), increasing direct ownership by 2% to 888,689 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/4/25 7:55:21 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Scientific Officer Micallef Jacob Vincent bought $21,500 worth of shares (50,000 units at $0.43), increasing direct ownership by 13% to 426,033 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 1:23:05 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Reynolds Cameron John bought $8,730 worth of shares (20,000 units at $0.44), increasing direct ownership by 0.87% to 2,319,222 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 12:43:56 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Financials

    Live finance-specific insights

    See more
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

      Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

      5/12/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

      Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference CallDate: Monday, March 31, 2025Time: 4:30 p.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fre

      3/25/25 9:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care